// App-Quantinova.ai

L14 : Bimekizumab Maintains Improvements in Efficacy Endpoints and Has a Consistent Safety Profile Through 52 Weeks in Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Results from Two Parallel Phase 3 Studies

Researchers

Presenter

  • Xenofon Baraliakos

Principal Investigators

  • Atul Deodhar

  • Désirée van der Heijde

  • Marina Magrey

  • Walter Maksymowych

  • Tetsuya Tomita

  • Huji Xu

  • Marga Oortgiesen

  • Ute Massow

  • Carmen Fleurinck

  • Alicia M Ellis

  • Tom Vaux

  • Julie Shepherd-Smith

  • Alexander Marten

  • Lianne S Gensler

Medical Centers

  • Rheumazentrum Ruhrgebiet, Herne, Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Department of Urology, Leiden Unviersity Medical Center, Leiden, Netherlands

  • Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH

  • Department of Surgery, University of Alberta, Edmonton, AB, Canada

  • Graduate School of Health Science, Morinomiya University of Medical Science, Osaka City, Osaka City, Osaka, Japan

  • Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Affiliated to Second Military Medical University, Shanghai, China (People's Republic)

  • UCB Pharma, Morrisville

  • UCB Pharma, Monheim, Nordrhein-Westfalen, Germany

  • UCLouvain, Brussels, Brussels Hoofdstedelijk Gewest, Belgium

  • UCB Pharma, Slough, UK Slough United Kingdom

  • Department of Medicine, Division of Gastroenterology, University of California, San Francisco, San Franciso, California, United States

Locations

  • Philippines

  • Germany

  • United States

  • Netherlands

  • Canada

  • Japan

  • China

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Musculoskeletal

Disease

  • Non-radiographic axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

  • Axial spondyloarthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03928704

  • NCT03928743

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved